Zagonel V, Tirelli U, Veronesi A, Galligioni E, Tumolo S, Roncadin M, Carbone A, Grigoletto E
Blut. 1986 Jan;52(1):59-61. doi: 10.1007/BF00320143.
Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.
Zotero 插件